(SVRA) Savara - Ratings and Ratios
Biopharmaceutical, Granulocyte, Colony-Stimulating Factor
SVRA EPS (Earnings per Share)
SVRA Revenue
Description: SVRA Savara
Savara Inc. is a clinical-stage biopharmaceutical company specializing in rare respiratory diseases, with a primary focus on molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for treating autoimmune pulmonary alveolar proteinosis (aPAP). The companys lead candidate has significant potential, given the severity and rarity of aPAP, a condition characterized by the accumulation of surfactant-like protein and phospholipids in the lungs, leading to impaired gas exchange.
From a financial perspective, Savaras market capitalization stands at approximately $378.51 million USD, indicating a relatively small-cap company with a high-risk, high-reward profile typical of the biotech sector. The absence of a price-to-earnings ratio (P/E) is not surprising, given that the company is still in the clinical development stage and not yet profitable. The return on equity (RoE) is negative at -65.88%, reflecting the significant investment in research and development without current profitability.
Key performance indicators (KPIs) to watch for Savara include the progression of molgramostim through Phase 3 trials, upcoming milestones such as FDA approval and commercial launch, and the companys cash burn rate, which will be crucial in determining its ability to achieve these milestones without needing additional capital. The companys ability to manage its cash reserves effectively will be vital, given its current financials and the capital-intensive nature of biotech development. Additionally, monitoring the competitive landscape for treatments of aPAP and other rare respiratory diseases will be essential in assessing Savaras market potential.
The stocks technical indicators suggest a volatile trading environment, with the stock price currently at $2.34, below both its 50-day and 200-day simple moving averages (SMA50 and SMA200), indicating a downtrend. The average true range (ATR) of 0.16, or approximately 6.99% of the current price, suggests significant short-term volatility. Investors should be cautious and closely monitor upcoming clinical trial results and corporate announcements for potential catalysts that could impact the stock price.
SVRA Stock Overview
| Market Cap in USD | 660m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2017-06-01 |
SVRA Stock Ratings
| Growth Rating | 25.8% |
| Fundamental | 22.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -29.2% |
| Analyst Rating | 4.25 of 5 |
SVRA Dividends
Currently no dividends paidSVRA Growth Ratios
| Growth Correlation 3m | 97.5% |
| Growth Correlation 12m | -55.4% |
| Growth Correlation 5y | 74.3% |
| CAGR 5y | 34.03% |
| CAGR/Max DD 3y | 0.52 |
| CAGR/Mean DD 3y | 1.65 |
| Sharpe Ratio 12m | -0.06 |
| Alpha | 0.15 |
| Beta | 0.000 |
| Volatility | 59.92% |
| Current Volume | 1075.3k |
| Average Volume 20d | 1556.3k |
| Stop Loss | 3.4 (-6.3%) |
| Signal | -0.09 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-110.3m TTM) > 0 and > 6% of Revenue (6% = 16.3k TTM) |
| FCFTA -0.54 (>2.0%) and ΔFCFTA -17.64pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.61 (>3.0%) and CFO -99.4m > Net Income -110.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 11.08 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (216.4m) change vs 12m ago 18.54% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.18% (prev 0.0%; Δ 0.18pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -23.78
| (A) 0.84 = (Total Current Assets 151.0m - Total Current Liabilities 13.6m) / Total Assets 163.8m |
| (B) -3.34 = Retained Earnings (Balance) -546.3m / Total Assets 163.8m |
| warn (B) unusual magnitude: -3.34 — check mapping/units |
| (C) -0.77 = EBIT TTM -116.4m / Avg Total Assets 151.7m |
| (D) -12.62 = Book Value of Equity -546.3m / Total Liabilities 43.3m |
| Total Rating: -23.78 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 22.48
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -16.00% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.36 = 2.44 |
| 5. Debt/Ebitda -0.37 = -2.50 |
| 6. ROIC - WACC (= -67.75)% = -12.50 |
| 7. RoE -69.05% = -2.50 |
| 8. Rev. Trend 30.57% = 2.29 |
| 9. EPS Trend -95.00% = -4.75 |
What is the price of SVRA shares?
Over the past week, the price has changed by -4.97%, over one month by +19.02%, over three months by +66.51% and over the past year by -15.97%.
Is Savara a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SVRA is around 3.77 USD . This means that SVRA is currently overvalued and has a potential downside of 3.86%.
Is SVRA a buy, sell or hold?
- Strong Buy: 4
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the SVRA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.8 | 169.7% |
| Analysts Target Price | 9.8 | 169.7% |
| ValueRay Target Price | 4.3 | 17.9% |
Last update: 2025-09-11 04:50
SVRA Fundamental Data Overview
CCE Cash And Equivalents = 146.4m USD (Cash And Short Term Investments, last quarter)
P/S = 131146.0
P/B = 5.4799
Beta = 0.556
Revenue TTM = 272.0k USD
EBIT TTM = -116.4m USD
EBITDA TTM = -116.2m USD
Long Term Debt = 29.7m USD (from longTermDebt, last quarter)
Short Term Debt = 13.6m USD (from totalCurrentLiabilities, last quarter)
Debt = 43.3m USD (Calculated: Short Term 13.6m + Long Term 29.7m)
Net Debt = 12.2m USD (from netDebt column, last quarter)
Enterprise Value = 557.1m USD (660.2m + Debt 43.3m - CCE 146.4m)
Interest Coverage Ratio = unknown (Ebit TTM -116.4m / Interest Expense TTM 0.0)
FCF Yield = -16.00% (FCF TTM -89.1m / Enterprise Value 557.1m)
FCF Margin = -32.8k% (FCF TTM -89.1m / Revenue TTM 272.0k)
Net Margin = -40.6k% (Net Income TTM -110.3m / Revenue TTM 272.0k)
Gross Margin = -27.57% ((Revenue TTM 272.0k - Cost of Revenue TTM 347.0k) / Revenue TTM)
Tobins Q-Ratio = -1.02 (set to none) (Enterprise Value 557.1m / Book Value Of Equity -546.3m)
Interest Expense / Debt = 3.34% (Interest Expense 1.44m / Debt 43.3m)
Taxrate = 21.0% (US default)
NOPAT = -116.4m (EBIT -116.4m, no tax applied on loss)
Current Ratio = 11.08 (Total Current Assets 151.0m / Total Current Liabilities 13.6m)
Debt / Equity = 0.36 (Debt 43.3m / last Quarter total Stockholder Equity 120.5m)
Debt / EBITDA = -0.37 (Net Debt 12.2m / EBITDA -116.2m)
Debt / FCF = -0.49 (Debt 43.3m / FCF TTM -89.1m)
Total Stockholder Equity = 159.8m (last 4 quarters mean)
RoA = -67.37% (Net Income -110.3m, Total Assets 163.8m )
RoE = -69.05% (Net Income TTM -110.3m / Total Stockholder Equity 159.8m)
RoCE = -61.43% (Ebit -116.4m / (Equity 159.8m + L.T.Debt 29.7m))
RoIC = -61.94% (NOPAT -116.4m / Invested Capital 187.9m)
WACC = 5.81% (E(660.2m)/V(703.5m) * Re(6.02%)) + (D(43.3m)/V(703.5m) * Rd(3.34%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 96.97 | Cagr: 3.22%
Discount Rate = 6.02% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -89.1m)
EPS Correlation: -95.00 | EPS CAGR: -52.32% | SUE: -1.41 | # QB: 0
Revenue Correlation: 30.57 | Revenue CAGR: 0.0%
Additional Sources for SVRA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle